← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › Synthetic anticholinergics, quaternary ammonium compounds
benzilone
A03AB01
Forms & Strengths
- Tablet: 5 mg
- Parenteral solution: 2 mg/mL
Adult Dosing
- Oral: 2 to 5 mg three to four times daily
- Intramuscular or Subcutaneous: 1 to 2 mg every 4 to 6 hours as needed
Pediatric Dosing
- Safety and efficacy not established in pediatric patients; use generally not recommended
Indications
- Adjunctive treatment of peptic ulcer disease
- Management of gastrointestinal hypersecretory and hypermotility disorders
Mechanism of Action
- Competitive antagonist at muscarinic acetylcholine receptors (anticholinergic/antispasmodic)
- Reduces gastric acid secretion, GI motility, and smooth muscle tone
Contraindications
- Hypersensitivity to benzilone or anticholinergic agents
- Narrow-angle glaucoma
- Obstructive uropathy or prostatic hypertrophy
- Obstructive disease of the gastrointestinal tract (e.g., achalasia, paralytic ileus, pyloroduodenal stenosis)
- Severe ulcerative colitis or toxic megacolon
- Myasthenia gravis
Adverse Reactions
- Xerostomia (dry mouth)
- Blurred vision and cycloplegia
- Constipation and urinary retention
- Tachycardia and palpitations
- Drowsiness, dizziness, and confusion (especially in elderly)
- Anhidrosis and decreased sweating
Drug Interactions
- Enhanced anticholinergic adverse effects with concomitant use of tricyclic antidepressants, antihistamines, and anti-parkinsonian agents
- Decreased gastrointestinal absorption of concurrent oral medications due to delayed gastric emptying and motility
Curated Content: Needs Vetting Before Put to Clinical Use